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BACKGROUND. Greater body mass index (BMI) is associated with shorter time to
prostate-specific antigen (PSA) failure following radical prostatectomy and radia-
tion therapy (RT). Whether BMI is associated with prostate cancer-specific mor-
tality (PCSM) was investigated in a large randomized trial of men treated with RT
and androgen deprivation therapy (ADT) for locally advanced prostate cancer.
METHODS. Between 1987 and 1992, 945 eligible men with locally advanced pros-
tate cancer were enrolled in a phase 3 trial (RTOG 85-31) and randomized to RT
and immediate goserelin or RT alone followed by goserelin at recurrence. Height
and weight data were available at baseline for 788 (83%) subjects. Cox regression
analyses were performed to evaluate the relations between BMI and all-cause
mortality, PCSM, and nonprostate cancer mortality. Covariates included age, race,
treatment arm, history of prostatectomy, nodal involvement, Gleason score, clini-
cal stage, and BMI.
RESULTS. The 5-year PCSM rate for men with BMI <25 kg/m2 was 6.5%, com-
pared with 13.1% and 12.2% in men with BMI 25 to <30 and BMI 30, respec-
tively (Gray’s P 5 .005). In multivariate analyses, greater BMI was significantly
associated with higher PCSM (for BMI 25 to <30, hazard ratio [HR] 1.52, 95%
confidence interval [CI], 1.02–2.27, P 5 .04; for BMI 30, HR 1.64, 95% CI, 1.01–
2.66, P 5 .04). BMI was not associated with nonprostate cancer or all-cause
mortality.
CONCLUSIONS. Greater baseline BMI is independently associated with higher
PCSM in men with locally advanced prostate cancer. Further studies are war-
ranted to evaluate the mechanism(s) for increased cancer-specific mortality and
to assess whether weight loss after prostate cancer diagnosis alters disease
course. Cancer 2007;110:2691–99.  2007 American Cancer Society.
KEYWORDS: obesity, BMI, mortality, prostate cancer, hormonal therapy, radiation
therapy.
O besity and prostate cancer are 2 important causes of morbidityand mortality afflicting men in the US.1–3 Approximately one-
third of American men are obese1 and greater than 218,000 men are
estimated to be diagnosed with prostate cancer in 2007.2 While cer-
tain types of cancer may occur more frequently and may be more
likely to be fatal in obese patients,4,5 observational studies remain
unclear as to the link between an elevated body mass index (BMI)
and risk of prostate cancer development.4–10
Greater BMI, however, has been shown to be associated with
more aggressive higher-grade prostate cancer11–13 and higher pros-
tate-specific antigen (PSA) recurrence rates following radical prosta-
tectomy (RP).11,14–16 The data following radiation therapy (RT) is
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limited. Two recent retrospective analyses suggested
that BMI is a predictor of PSA failure among patients
treated with external beam RT with or without andro-
gen deprivation therapy (ADT),17,18 while another
report suggested that this may not be the case fol-
lowing brachytherapy.19 Biochemical failure, however,
only weakly correlates with risk of cancer-specific
mortality.20,21 Survival after RP may not be affected
by BMI22 and the effect after RT is unknown.
Several phase 3 randomized trials have demon-
strated a survival benefit to adjuvant ADT for
patients with locally advanced or high-grade prostate
cancer.23–26 Based on evidence of improved survival,
the use of hormonal therapy in addition to RT has
increased markedly.27 Yet ADT exposes patients to a
number of potential adverse effects, including weight
gain and increased fat mass.28,29 Whether obesity
influences overall or disease-specific outcomes in
men treated with RT and ADT is unknown.
In this study we investigated the relations
between BMI and prostate cancer-specific mortality
(PCSM), noncancer mortality, and overall mortality
using data from a large-scale randomized trial of
men treated with RT and ADT for locally advanced
prostate cancer.
MATERIALS AND METHODS
Radiation Therapy Oncology Group (RTOG) protocol
85-31 was a phase 3 trial designed to compare the
effectiveness of adjuvant ADT with goserelin, a go-
nadotropin-releasing hormone (GnRH) agonist, given
in addition to standard external beam RT versus the
use of ADT therapeutically following RT at the time
of recurrence in a population of patients with locally
advanced prostate cancer.24
Patient Eligibility
All subjects had histologically confirmed adenocarci-
noma of the prostate and either had grossly palpable
tumor beyond the confines of the prostate (clinical
stage T3) or documented involvement of the regional
lymphatics. Patients with primary tumor confined to
the prostate (clinical stage T1-2) were eligible if there
was evidence of spread to the regional lymph nodes
either radiographically or histologically. Patients with
bulky primary lesions (product of palpable tumor
dimensions 25 cm) were not eligible for this study,
but were for a parallel study (RTOG 86-10). Excep-
tions were those with evidence of spread to lympha-
tics outside the pelvis (common iliac and/or
paraaortic) who were eligible regardless of the pri-
mary tumor size. Patients who had undergone RP
were eligible if penetration through the prostatic
capsule to the resection margin and/or to the semi-
nal vesicles was histologically documented. The
Karnofsky performance status had to be >60%. All
institutional state and federal guidelines had to be
followed. All patients provided written informed con-
sent before study enrollment.
Pretreatment Evaluation
Pretreatment evaluation included history and physi-
cal examination. Laboratory studies included serum
acid phosphatase, complete blood cell count, serum
testosterone determination, and, after July 1990, PSA
measurement. PSA determination was not mandatory
at study inception because it was not widely avail-
able. Radiographic evaluation included chest x-ray
and bone scan. Lymph node assessment was manda-
tory by lymphangiography, computed tomography
(CT), or lymphadenectomy.
Study Design
Patients were entered in the study by a telephone call
to RTOG headquarters within the first week of RT. After
confirmation of eligibility, patients were stratified by
histologic differentiation (well-differentiated or Glea-
son score 2–5; moderately differentiated or Gleason
score 6–7; and poorly differentiated or Gleason score
8–10), nodal status and extent of nodal involvement
(none vs involvement below common iliacs vs com-
mon iliac involvement vs paraaortic involvement),
acid phosphatase status (not elevated vs elevated),
and prior RP (no vs yes). The randomization scheme
described by Zelen30 was used to achieve balance in
treatment assignment among institutions using the 4
stratification variables.24 Patients were randomized
either to RT and adjuvant goserelin (Arm I) or to RT
alone followed by observation and administration of
goserelin at recurrence (Arm II). Among patients
assigned to Arm I, ADT was to be started during the
last week of RT and was to be continued indefinitely
or until signs of progression. Among patients
assigned to Arm II, ADT was to start as soon as re-
currence (local and/or distant) was established.
Treatment
Radiation technique
All patients received RT on megavoltage units with a
multiple field technique. The initial target volume
(prostate plus draining lymph nodes) received a total
dose of 44–46 Gy. The prostatic target volume was to
receive a boost dose of 20–25 Gy, which brought the
total prescribed dose to 65–70 Gy. Among postopera-
tively (ie, following RP) irradiated patients, the pros-
tatic bed was to receive 60–65 Gy and irradiation of
the regional lymphatics was not required if there was
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no histopathologic evidence of lymph node involve-
ment. In all cases a boost target volume was
designed to include the prostate with margins suffi-
ciently wide to encompass all tumor extensions into
surrounding tissues. The daily dose was 1.8–2.0 Gy
per fraction, given 4 to 5 times weekly.
In designing the initial fields the inferior border
was set at a projection point located 5–6 cm below
the superior margin of the symphysis. Among
patients with evidence of tumor spread to the pelvic
lymphatics (obturator, external and internal iliac),
the superior border of the initial target volume was
placed at the L5-S1 interspace. If the common iliac
chain was involved the superior border was raised to
the level of the L2-L3 interspace, and if the paraaor-
tic nodes were involved it was raised to encompass
vertebral body T11. The lateral borders of the initial
fields were placed 2 cm lateral to the pelvic brim.
Although it was known that the amount of radiation
selected for gross nodal disease was unlikely to pro-
vide control, the protocol was not written to include
higher doses, since conformal techniques were not
widely available during the study period.
Drug therapy
Subjects assigned to Arm I were treated with gosere-
lin acetate (Zoladex, Zeneca Pharmaceutical, Wil-
mington, Del) (3.6 mg subcutaneously in the anterior
abdominal wall monthly), started during the last
week of RT. Subjects in Arm II were treated with
goserelin at recurrence. In both arms goserelin was
continued indefinitely or until sign of disease
progression.
Data Collection and Analysis
Central review of radiation therapy delivered, calibra-
tion of all machines on which a patient was treated,
and review of materials on which the diagnosis was
based were performed for each case as per the usual
RTOG/National Cancer Institute (NCI) requirements.24
Body mass index
BMI (weight in kilograms divided by height in meters
squared [kg/m2]) was calculated using patient height
and weight data as measured at baseline. BMI was
categorized as per the National Institutes for Health
classifications, with individuals with a BMI <25 kg/
m2 considered normal, those with a BMI of 25–29.9
kg/m2 considered overweight, and those with a BMI
30 kg/m2 considered obese.31
Survival endpoints
Prostate cancer-specific mortality (PCSM) was
defined as death from prostate cancer or protocol
treatment. Non-PCSM was defined as death from
any cause other than prostate cancer or protocol
treatment. All-cause mortality (ACM) was defined as
death from any cause. These endpoints were meas-
ured from the date of randomization to the date of
death or most recent follow-up through 2005.
Statistical methods
Chi-square test statistics were used to compare pre-
treatment characteristics of patients at study entry.
The cumulative incidence method32 was used to esti-
mate times to PCSM and non-PCSM because it spe-
cifically adjusts for other competing causes of
mortality. Gray’s test statistic33 for comparing cumu-
lative incidence rates was used. ACM was estimated
according to the Kaplan-Meier method34 and com-
parisons were performed with the log-rank test.35
Univariate Cox proportional hazard regression analy-
ses36 using the chi-square test were performed to
evaluate the solitary effect of each variable on the
various survival endpoints. To analyze whether BMI
was independently associated with PCSM, non-
PCSM, and ACM while adjusting for known prognos-
tic factors, multivariate analyses were performed
using a Cox proportional hazards regression model36
with the following categorical covariates: age (<70
[reference level] vs 70 years), race (black [reference
level] vs white/other), centrally reviewed Gleason
score (2–6 [reference level] vs 7–10), clinical stage (A/
B [reference level] vs C), nodal involvement (no [ref-
erence level] vs yes), prostatectomy (no [reference
level] vs yes), treatment (Arm II [reference level] vs
Arm I), and BMI (<25 [reference level] vs 25–30 vs
30 kg/m2). For the categorical variables the cut-
points selected were made before the data were
examined and were based on established strata.24,31
BMI was also analyzed as a continuous variable.
Unadjusted and adjusted hazard ratios (HRs) were
calculated for all covariates using the Cox propor-
tional hazards model with associated 95% confidence
intervals (CIs) and P-values. All statistical compari-
sons were 2-sided and a P-value <.05 was considered
statistically significant. Statistical Analysis System




Between February 1987 and April 1992, when the
study was closed, a total of 977 patients were
entered, 488 on Arm I and 489 on Arm II. Thirty-two
patients were retrospectively classified as ineligible
and excluded from the subsequent analysis, leaving
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945 eligible patients, 477 on Arm I and 468 on Arm
II. Height and weight data were available at baseline
for 788 (83%) of these subjects and the current analy-
ses are restricted to this subset. As shown in Table 1,
pretreatment characteristics, including median BMI
and BMI categorization, were similar according to
the treatment arms. The median BMI was 26.6 kg/m2
(range, 14.7–47.9). In all, 241 (31%) of subjects were
categorized as having normal weight, 402 (51%) as
overweight, and 145 (18%) as obese.
Main Study Outcomes
Figure 1 graphically displays the main outcomes of
PCSM, non-PCSM, and ACM for the 788 subjects
with available BMI. The median follow-up was 8.1
(range, 0.2–15.1) years overall. There were a total of
476 deaths, 169 of which were prostate cancer-
related. As shown in Table 2, men treated with im-
mediate ADT on Arm I were significantly less likely
TABLE 1
Pretreatment Characteristics
Arm I Arm II
P
(n 5 403) (n 5 385)
No. % No. %
Age, y
<70 191 47 181 47 .91
70 212 53 204 53
Race
White 361 90 347 90 .80
Black 37 9 35 9
Other 5 1 3 1
Prostatectomy
No 338 84 324 84 .91
Yes 65 16 61 16
Nodal involvement
No 283 70 285 74 .23
Yes 120 30 100 26
Gleason score (central)
Score missing 31 8 35 9
Score available 372 92 350 91
2–6 104 28 99 28 .92
7–10 268 72 251 72
Clinical stage
A/B 122 30 106 28 .40
C 281 70 279 72
BMI (kg/m2)
BMI category
<25 132 33 109 28 .40
25 to <30 200 50 202 52
30 71 18 74 19
BMI, median (kg/m2) 26.6 26.6
BMI, range (kg/m2) 16.2–44.8 14.7–47.9
BMI indicates body mass index.
FIGURE 1. Time to (top) prostate cancer-specific mortality (PCSM);
(middle) non-PCSM; and (bottom) all-cause mortality (ACM) by treatment arm
for the 788 subjects with available body mass index (BMI).
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than men on Arm II to die of prostate cancer or of
any cause. At 5 years, PCSM was 8.5% for Arm I ver-
sus 13.6% for Arm II (HR 0.65, 95% CI 0.48–0.88,
P 5 .006) and ACM was 23.8% for Arm I versus 29.1%
for Arm II (HR 0.79, 95% CI 0.66–0.94, P 5 .003).
Effect of BMI: Univariate Analysis
On univariate analysis, the 5-year PCSM rate for men
with BMI <25 kg/m2 was 6.5%, compared with 13.1%
in men with BMI 25 to <30 and 12.2% in men with
BMI 30 (Gray’s P 5 .005) (Table 2). Overweight and
obese patients were approximately 1.8 times more
likely to die of prostate cancer than those with nor-
mal weight (HR 1.78 [95% CI 1.20–2.63, P 5 .004] and
HR 1.79 [95% CI 1.13–2.86, P 5 .014], respectively).
Figure 2 graphically displays the time to PCSM by
BMI category.
Effect of BMI: Multivariate Analysis
Results of the multivariate analysis are shown in
Table 3. After adjusting for age, race, treatment arm,
history of prostatectomy, nodal involvement, Gleason
score, and clinical stage, a greater BMI remained sig-
nificantly associated with higher PCSM (for BMI
25- <30, adjusted HR 1.52, 95% CI 1.02–2.28,
P 5 .04; for BMI 30, adjusted HR 1.64, 95% CI
1.01–2.66, P 5 .04). Results were similar when BMI
was analyzed as a continuous variable (data not
shown). Delayed ADT (P 5 .0004), no history of pros-
tatectomy (P 5 .01), presence of nodal involvement
(P 5 .0002), and Gleason 7–10 cancer (P < .0001)
were also significantly associated with higher PCSM.
BMI was not associated with non-PCSM or ACM.
DISCUSSION
Using data from a large, multicenter, randomized
controlled trial with long follow-up, we found that a
greater baseline BMI is independently associated
with higher cancer-specific mortality in men with
locally advanced prostate cancer. Compared with
TABLE 2
Univariate Analyses of Survival Outcomes Stratified by (A) Treatment Arm and (B) BMI Category
A: Outcome Treatment arm No. No. events 5-year failure rate (95% CI) Unadjusted HR (95% CI) P*
Prostate cancer-specific mortality Arm II 385 95 13.6 (10.1, 17.1) —
Arm I 403 72 8.5 (5.7, 11.2) 0.65 (0.48, 0.88) .006
Nonprostate cancer-specific mortality Arm II 385 153 15.5 (11.8, 19.2) —
Arm I 403 156 15.3 (11.8, 18.9) 0.87 (0.70, 1.09) .23
All-cause mortality Arm II 385 248 29.1 (24.5, 33.7) —
Arm I 403 228 23.8 (19.6, 28.0) 0.79 (0.66, 0.94) .003
B: Outcome BMI Category No. No. events 5-Year Failure Rate (95% CI) Unadjusted HR (95% CI) P*
Prostate cancer-specific mortality <25 241 34 6.5 (3.3, 9.6) —
25, <30 402 98 13.1 (9.8, 16.5) 1.78 (1.20, 2.63) .004
30 145 37 12.2 (6.7, 17.6) 1.79 (1.13, 2.86) .014
Nonprostate cancer-specific mortality <25 241 109 15.2 (10.6, 19.9) —
25, <30 402 152 15.9 (12.3, 19.5) 0.87 (0.68, 1.11) .26
30 145 48 14.4 (8.5, 20.3) 0.71 (0.51, 1.00) .052
All-cause mortality <25 241 143 21.7 (16.4, 26.9) —
25, <30 402 248 29.0 (24.6, 33.5) 1.08 (0.88, 1.33) .44
30 145 85 26.6 (19.3, 33.8) 0.97 (0.74, 1.27) .82
BMI indicates body mass index; CI, confidence interval; HR, hazard ratio.
* P-value from chi-square test using the Cox proportional hazards model.
FIGURE 2. Time to prostate cancer-specific mortality (PCSM) by body
mass index (BMI) category.
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men with normal BMI, overweight and obese men
had an approximately 2-fold greater risk of prostate
cancer-related death. Specifically, at 5 years the
PCSM rate for men with normal BMI was 6.5%, com-
pared with 13.1% for overweight men and 12.2% for
obese men. To the best of our knowledge, this is the
first large study using prospective data to evaluate
the relationship between obesity and mortality in
men treated for locally advanced prostate cancer.
Our findings are consistent with a recent popula-
tion-based case-control study37 and epidemiologic
studies.5,6,38,39 In a prospective study of 135,000
Swedish construction workers with more than 18
years of follow-up, obesity was associated with about
a 40% increased risk of PCSM than a normal BMI.6 A
study of 6763 Seventh-day Adventists followed
between 1960 and 1980 reported that the risk of fatal
prostate cancer was 2.5 times higher in overweight
compared with normal weight men, and even higher
in those who heavily consumed animal products.39
In 2 large prospective cohorts known as the Cancer
Prevention Study (CPS) I and II, the American Cancer
Society followed 816,268 men enrolled in 1959 and
again in 1982, respectively, among whom there were
5212 prostate cancer deaths.38 Both CPS I and II
reported that obese men (BMI 30 kg/m2) had sig-
nificantly higher PCSM rates than normal weight
men, with a 27% and 21% increased risk of death,
respectively. In a more recent update of CPS II with
16 years of follow-up,5 severely obese men
(BMI >35 kg/m2) were at an even greater risk (34%)
of prostate cancer death relative to normal weight
men.
Several mechanisms may account for the shorter
cancer-specific survival among obese men. Obesity is
associated with higher estradiol, lower testosterone,
and lower sex hormone-binding globulin levels and
this microenvironment may predispose to more
aggressive disease.40–42 Low baseline serum testoster-
one levels are associated with a higher incidence of
extracapsular disease in men undergoing RP for
early-stage prostate cancer40 and shorter overall sur-
TABLE 3
Multivariate Analyses of Survival Outcomes
Outcome Covariate Comparison HR (95% CI) P
Prostate cancer-specific mortality Age <70 vs 70 1.21 (0.86, 1.70) .27
Race Black vs Other 0.9 (0.52, 1.56) .72
Treatment arm Arm II vs Arm I 0.57 (0.41, 0.78) .0004
Prostatectomy No vs Yes 0.51 (0.30, 0.87) .013
Nodal involvement No vs Yes 2.22 (1.46, 3.37) .0002
Gleason score (Central review) 2–6 vs 7–10 3.47 (2.19, 5.49) <.0001
Clinical stage A-B vs C 1.28 (0.82, 2.02) .28
BMI <25 —
25, <30 1.52 (1.02, 2.28) .041
30 1.64 (1.01, 2.66) .043
Nonprostate cancer-specific mortality Age <70 vs 70 2.12 (1.62, 2.77) <.0001
Race Black vs Other 0.72 (0.49, 1.07) .11
Treatment arm Arm II vs Arm I 0.83 (0.66, 1.05) .12
Prostatectomy No vs Yes 0.58 (0.36, 0.93) .025
Nodal involvement No vs Yes 1.28 (0.89, 1.84) .19
Gleason score (Central review) 2–6 vs 7–10 1.43 (1.10, 1.85) .008
Clinical stage A-B vs C 1.60 (1.05, 2.43) .029
BMI <25 —
25, <30 0.95 (0.73, 1.23) .70
30 0.77 (0.53, 1.11) .16
All-cause mortality Age <70 vs 70 1.72 (1.40, 2.12) <.0001
Race Black vs Other 0.78 (0.57, 1.08) .13
Treatment arm Arm II vs Arm I 0.73 (0.60, 0.88) .0008
Prostatectomy No vs Yes 0.54 (0.38, 0.78) .0009
Nodal involvement No vs Yes 1.60 (1.22, 2.10) .0007
Gleason score (Central review) 2–6 vs 7–10 1.84 (1.48, 2.30) <.0001
Clinical stage A-B vs C 1.46 (1.07, 1.98) .016
BMI <25 —
25, <30 1.09 (0.88, 1.36) .42
30 1.00 (0.75, 1.33) 1.00
BMI indicates body mass index; HR, hazard ratio; CI, confidence interval.
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vival in men with metastatic prostate cancer.43 Obe-
sity is linked to insulin resistance and diabetes.44 In-
sulin and insulin-like growth factors (IGFs) may
promote prostate cancer progression.45,46 In addition,
elevated leptin and lower adiponectin levels among
obese men have been implicated in prostate cancer
aggressiveness.47–49
Clinical understaging of the extent of disease
may also contribute to increased PCSM in obese
men. Obese men tend to have larger prostate
glands22,50 and their body habitus may interfere with
digital rectal examination. In prostatectomy series
that control for adverse pathologic features such as
Gleason sum, stage, extracapsular extension, seminal
vesicle invasion, margin status, and lymph node me-
tastases, however, there remains an association
between increased BMI and risk of biochemical pro-
gression.14,15 Obese patients may have lower serum
PSA values51 due to lower testosterone and higher
estradiol levels but increased pretreatment PSA
velocity.52 Notably, we cannot comment on this effect
given that RTOG 85-31 was conducted before PSA
screening was widely available.
Decreased effectiveness of local therapy may also
contribute to shorter cancer-specific survival in over-
weight and obese men. Obese men have greater risk
of positive surgical margins following RP.11,14,22 Simi-
larly, greater organ motion and set-up error may
interfere with accurate delivery of RT to obese
men.53,54 Notably, these technical problems may be
of even greater concern in the very obese.
Hormone therapy may also be less effective in
obese men. Despite lower pretreatment serum testos-
terone levels, obese men have significantly higher
testosterone levels during treatment with gonadotro-
pin-releasing hormone (GnRH) agonists than men
with normal BMI.55 The substantially smaller relative
decline in testosterone levels after GnRH agonist
treatment may contribute to greater cancer-specific
mortality in obese men. Additional research is
needed to further delineate the relationships between
obesity, sex steroid levels, and survival in men receiv-
ing ADT.
Obesity is associated with greater ACM in the
general population. The relative increase in mortality
associated with obesity is modest, however, and has
required very large population-based studies with
long follow-up. For example, in a 12-year prospective
cohort study of over 1 million Koreans,56 overweight
and obese men and women had higher rates of death
than those of normal weight. In other prospective
cohort studies of over 500,000 US adults57 and
approximately 170,000 Chinese men and women,58
obesity was associated with increased mortality. In
another study from the National Health and Nutri-
tional Examination Surveys (NHANES) I-III,3 obesity
(and particularly higher levels of obesity), but not
overweight, was associated with excess deaths rela-
tive to the normal weight category. Given the number
of subjects in our study, it is thus not surprising that
we did not observe a significant association between
BMI and non-PCSM or ACM. Moreover, our locally
advanced patient population was at a high risk for
PCSM.
Potential limitations of this study need to be
considered. BMI data were collected prospectively
but not originally to understand the association
between obesity and PCSM. We lack information on
lifestyle factors, such as diet and physical activity,
which may mediate some of the effect of obesity on
cancer-specific mortality. Our analyses were re-
stricted to baseline BMI. Further studies are war-
ranted to assess the impact of obesity earlier in life,
weight changes over time, and the impact of weight
loss on the clinical course of disease. Since ADT itself
is known to cause weight gain and increase fasting
insulin levels, as well as decrease insulin sensitiv-
ity,28,29,59 it will be important to investigate whether
such adverse effects of therapy have an independent
effect on outcomes.
In conclusion, we found that a greater baseline
BMI is independently associated with higher cancer-
specific mortality in men with locally advanced pros-
tate cancer. Further studies are warranted to evaluate
the mechanisms for this increased mortality among
obese men and to assess the impact of BMI on sur-
vival following other management strategies and in
clinically localized disease. Whether weight loss after
prostate cancer diagnosis can alter the disease course
remains to be determined.
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